NCT05269849View on ClinicalTrials.gov

Sirolimus for Nosebleeds in HHT

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions
Hereditary Hemorrhagic TelangiectasiaNosebleedsEpistaxis
Interventions
DRUG

Sirolimus

Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months

Trial Locations (1)

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

University of California, San Francisco

OTHER

lead

Unity Health Toronto

OTHER